Results 111 to 120 of about 9,804 (228)

Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry. [PDF]

J Gastroenterol Hepatol, 2022
Wong YJ, Kumar R, Kumar R, Tan J, Liu CH, Hui VK, Tan SS, Kao JH, Wong GH, Thurairajah PH.   +9 more
europepmc   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

Daclatasvir: potential role in hepatitis C

Drug Design, Development and Therapy, 2013
Choongho Lee College of Pharmacy, Dongguk University-Seoul, Goyang, Republic of Korea  Abstract: Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma.
Lee C
doaj  

Analysis of genetic polymorphisms and drug resistance mutations in the NS5 region of HCV genome (Flasuviricetes: Amarillovirales: Flaviviridae: Hepacivirus C) in samples obtained in 2022–2023 from HIV-infected treatment-naive residents of Altai Krai

Вопросы вирусологии
Introduction. Altai Krai is a region with an unfavorable situation of HIV-1 and HCV infection, as well as HIV-1 and HCV coinfection. Due to this, it is necessary to study the HCV genetic variants and their drug resistance (DR) to direct-acting antivirals
Ilya A. Lapovok, Arina V. Syrkina, Alina A. Kirichenko, Anastasia V. Shlykova, Natalya V. Lukyanenko, Tatyana V. Safyanova, Arina E. Safronova, Valery V. Shevchenko, Dmitry E. Kireev   +8 more
doaj   +1 more source

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done

Annals of Hepatology, 2019
Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge.
Susana Llerena, Joaquín Cabezas, Antonio Cuadrado, José Manuel Olmos, Marta González, Federico García, Carmen Cobo, Javier Crespo   +7 more
doaj   +1 more source

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection

Annals of Hepatology, 2018
Background and aim. Grazoprevir is an NS3/4A protease inhibitor (PI), while elbasvir is an NS5A inhibitor. We performed this meta-analysis to directly compare grazoprevir plus elbasvir and ribavirin regimen vs.
Hussien Ahmed, Abdelrahman Ibrahim Abushouk, Amr Menshawy, Attia Attia, Arwa Mohamed, Ahmed Negida, Mohamed M. Abdel-Daim   +6 more
doaj   +1 more source

Противовирусные лекарственные средства для лечения гепатита C [PDF]

, 2019
ГЕПАТИТ C /ЛЕК ТЕРПАРЕНТЕРАЛЬНО-ПЕРЕДАВАЕМЫЙ ГЕПАТИТ НИ-A, НИ-B /ЛЕК ТЕРПРОТИВОВИРУСНЫЕ СРЕДСТВА /ХИМЛЕКАРСТВ ХИМИЧЕСКАЯ СТАБИЛЬНОСТЬИНГИБИТОРЫ ПРОТЕАЗЫ NS3/NS4АИНГИБИТОРЫ БЕЛКА NS5AИНГИБИТОРЫ NS5B ПОЛИМЕРАЗЫДан обзор химической структуры и её связи с ...
Жерносек, А. К., Лагодич, А. С.   +1 more
core  

Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells [PDF]

, 2009
The primary reservoir for hepatitis C virus (HCV) replication is believed to be hepatocytes, which are highly polarized with tight junctions (TJ) separating their basolateral and apical domains.
Balfe, Peter, Davis, Christopher, Farquhar, Michelle J, Harris, Helen J, McKeating, Jane A, Mee, Christopher J, Reynolds, Gary, van IJzendoorn, Sven C D, Wilson, Garrick   +8 more
core   +3 more sources

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

International Journal of Women's Health, 2019
Christophe Hézode,1 Paul Kwo,2 Jan Sperl,3 Peggy Hwang,4 Jianmin Long,4 Rohit Talwani,4 Michael N Robertson,4 Barbara A Haber4 1Service d’Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Cr ...
Hézode C, Kwo P, Sperl J, Hwang P, Long J, Talwani R, Robertson MN, Haber BA   +7 more
doaj  

Hepatitis C virus infection and related liver disease: the quest for the best animal model [PDF]

, 2013
Hepatitis C virus (HCV) is a major cause of cirrhosis and hepatocellular carcinoma (HCC) making the virus the most common cause of liver failure and transplantation.
Baumert, Thomas F, Mailly, Laurent, Meuleman, Philip, Robinet, Eric, Zeisel, Mirjam   +4 more
core   +3 more sources